秋水仙碱在COVID-19并发症中的治疗潜力。一种古老且廉价药物的免疫代谢特性能否有所帮助？
The therapeutic potential of colchicine in the complications of COVID19. Could the immunometabolic properties of an old and cheap drug help?
作者信息
Ribeiro Sandro Augusto, Lopes Cassio, Amaral Ricardo, Amaral Adilaine
机构信息
Hospital John Paul II, Intensive Medical Assistance, AMI, Porto Velho, RO, Brazil.
Ministry of Health, Montes Claros, MG, Brazil.
出版信息
Metabol Open. 2020 Jul 21;7:100045. doi: 10.1016/j.metop.2020.100045. eCollection 2020 Sep.
The present study analyzes the importance of the inflammasome that involves the NLRP3 complex in the state of hypercytokinemia observed in patients with COVID-19, significantly increasing IL-1β, IL18, IL-6, and TNF. Unfortunately, improving the immune response can sometimes worsen the outcome of the disease. Studies show that colchicine, among other actions, inhibits the assembly of NLRP3 complex that is responsible for generating the active form of Caspase-1 that will convert Pro-IL-1β and Pro-IL-18 into their active forms. We suggest using colchicine, a class of drugs with low-cost, extensively tested, well-tolerated medicine as a complementary treatment for patients with COVID-19, in early stages of the disease based on knowledge of its immunomodulatory properties.
本研究分析了炎症小体（涉及NLRP3复合物）在新冠肺炎患者高细胞因子血症状态中的重要性，该状态会显著增加白细胞介素-1β（IL-1β）、白细胞介素-18（IL-18）、白细胞介素-6（IL-6）和肿瘤坏死因子（TNF）。不幸的是，改善免疫反应有时会使疾病的结局恶化。研究表明，秋水仙碱除其他作用外，可抑制NLRP3复合物的组装，该复合物负责产生半胱天冬酶-1的活性形式，后者会将白细胞介素-1β前体（Pro-IL-1β）和白细胞介素-18前体（Pro-IL-18）转化为它们的活性形式。基于秋水仙碱的免疫调节特性，我们建议在疾病早期，将秋水仙碱这种低成本、经过广泛测试且耐受性良好的药物作为新冠肺炎患者的辅助治疗药物。
Zotero 插件